{"id":"NCT01928771","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma","officialTitle":"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-19","primaryCompletion":"2016-04-05","completion":"2016-04-05","firstPosted":"2013-08-27","resultsPosted":"2017-05-03","lastUpdate":"2017-05-03"},"enrollment":2681,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab 30 mg q.4 weeks","type":"EXPERIMENTAL"},{"label":"Benralizumab 30 mg q.8 weeks","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.","primaryOutcome":{"measure":"Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL","timeFrame":"Immediately following the first administration of study drug through Study Week 48.","effectByArm":[{"arm":"Benralizumab 30 mg q.4 Weeks","deltaMin":0.73,"sd":null},{"arm":"Benralizumab 30 mg q.8 Weeks","deltaMin":0.65,"sd":null},{"arm":"Placebo","deltaMin":1.33,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":275,"countries":["United States","Australia","Brazil","Bulgaria","Czechia","France","Italy","Mexico","Peru","Poland","Russia","South Africa","South Korea","Spain","Turkey (Türkiye)","United Kingdom","Vietnam"]},"refs":{"pmids":["35287231","32334141","31836949","31626906","30802500","30139780","30077185","29409951","27609408"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1845&filename=D3250C00017_Revised_CSP_SIROCCO.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":403},"commonTop":["Nasopharyngitis","Asthma","Upper respiratory tract infection","Headache","Bronchitis"]}}